ECSP066810A - Derivados de carbamato de 2h- ó 3h-benzo[e]indazol-1-ilo, su preparación y su aplicación en terapéutica - Google Patents
Derivados de carbamato de 2h- ó 3h-benzo[e]indazol-1-ilo, su preparación y su aplicación en terapéuticaInfo
- Publication number
- ECSP066810A ECSP066810A EC2006006810A ECSP066810A ECSP066810A EC SP066810 A ECSP066810 A EC SP066810A EC 2006006810 A EC2006006810 A EC 2006006810A EC SP066810 A ECSP066810 A EC SP066810A EC SP066810 A ECSP066810 A EC SP066810A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- aryl
- groups
- therapeutics
- fluoroalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La invención se refiere a compuestos de la fórmula general (I): en la que W representa un átomo de oxígeno o de azufre; X1, X2, X3 y X4 representan cada uno de manera independiente el uno del otro, un átomo de hidrógeno o de halógeno o un grupo ciano, alquilo-C1 C6, fluoroalquilo-C1 C6, alcoxi-C1 C6 o fluoroalcoxi-C1 C6; Y está en posición (N2) o (N3); cuando Y está en posición (N2), Y representa un grupo alquilo-C1 C6, fluoroalquilo-C1 C6, arilo o heteroarilo; cuando Y está en posición (N3), Y representa un grupo arilo o heteroarilo; estando los grupos arilo o heteroarilo sustituidos opcionalmente con uno o varios átomos o grupos elegidos entre los átomos de halógeno, grupos alquilo-C1 C6, alcoxi-C1 C6, alquiltio-C1 C6, alquilo-C1 C6-S(O)-, alquilo-C1 C6-S(O)2- o fluoroalquilo-C1 C6; el enlace en posición C4-C5 es doble o sencillo; R1 y R2 representan cada uno, de manera independiente el uno del otro, un grupo arilo, bencilo o alquilo-C1 C6; o bien R1 y R2 forman, con el átomo de nitrógeno que los contiene un heterociclo sustituido opcionalmente con uno o varios grupos alquilo-C1 C6 o bencilo; en forma de base o de sal de adición de ácido, así como en forma de hidrato o de solvato. Proceso de preparación y aplicación en terapéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0405055A FR2870239B1 (fr) | 2004-05-11 | 2004-05-11 | Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique. |
| PCT/FR2005/001154 WO2005121099A1 (fr) | 2004-05-11 | 2005-05-10 | Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066810A true ECSP066810A (es) | 2006-11-16 |
Family
ID=34947852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006810A ECSP066810A (es) | 2004-05-11 | 2006-08-29 | Derivados de carbamato de 2h- ó 3h-benzo[e]indazol-1-ilo, su preparación y su aplicación en terapéutica |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7501449B2 (es) |
| EP (1) | EP1747201B8 (es) |
| JP (1) | JP4909889B2 (es) |
| KR (1) | KR101165483B1 (es) |
| CN (1) | CN100577648C (es) |
| AR (1) | AR049090A1 (es) |
| AT (1) | ATE411295T1 (es) |
| AU (1) | AU2005251982B2 (es) |
| BR (1) | BRPI0508563A (es) |
| CA (1) | CA2557942C (es) |
| CR (1) | CR8570A (es) |
| CY (1) | CY1108710T1 (es) |
| DE (1) | DE602005010418D1 (es) |
| DK (1) | DK1747201T3 (es) |
| EC (1) | ECSP066810A (es) |
| ES (1) | ES2315898T3 (es) |
| FR (1) | FR2870239B1 (es) |
| HK (1) | HK1104288A1 (es) |
| HR (1) | HRP20090012T3 (es) |
| IL (1) | IL177632A (es) |
| MA (1) | MA28372A1 (es) |
| NO (1) | NO20064073L (es) |
| NZ (1) | NZ549330A (es) |
| PL (1) | PL1747201T3 (es) |
| PT (1) | PT1747201E (es) |
| RS (1) | RS50724B (es) |
| RU (1) | RU2379293C2 (es) |
| SI (1) | SI1747201T1 (es) |
| TN (1) | TNSN06258A1 (es) |
| TW (1) | TWI349004B (es) |
| UA (1) | UA85866C2 (es) |
| WO (1) | WO2005121099A1 (es) |
| ZA (1) | ZA200607244B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2870239B1 (fr) | 2004-05-11 | 2006-06-16 | Sanofi Synthelabo | Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique. |
| WO2007088528A1 (en) * | 2006-02-03 | 2007-08-09 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Microtubule targeting agents |
| CL2008000793A1 (es) * | 2007-03-23 | 2008-05-30 | Xenon Pharmaceuticals Inc | Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro. |
| AU2014292164C1 (en) * | 2013-07-15 | 2018-09-27 | Basf Se | Pesticide compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0607076A1 (fr) * | 1993-01-15 | 1994-07-20 | Synthelabo | Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA |
| FR2741073B1 (fr) * | 1995-11-09 | 1997-12-12 | Synthelabo | Derives de 4,5-dihydroimidazo(1,2-a)pyrrolo(1,2,3-cd) benzimidazole, leur preparation et leur application en therapeutique |
| ID16283A (id) * | 1996-03-20 | 1997-09-18 | Astra Pharma Prod | Senyawa yang berguna dibidang farmasi |
| ZA9810490B (en) * | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| WO1999058117A1 (fr) * | 1998-05-13 | 1999-11-18 | Sanofi-Synthelabo | Utilisation de composes reduisant l'apoptose |
| MXPA03001945A (es) * | 2000-09-06 | 2003-09-10 | Neurogen Corp | Tetrahidroindazoles sustituidos con arilo y su uso como ligandos para el receptor gaba-a. |
| FR2870239B1 (fr) * | 2004-05-11 | 2006-06-16 | Sanofi Synthelabo | Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique. |
-
2004
- 2004-05-11 FR FR0405055A patent/FR2870239B1/fr not_active Expired - Fee Related
-
2005
- 2005-05-09 AR ARP050101865A patent/AR049090A1/es unknown
- 2005-05-10 AT AT05770962T patent/ATE411295T1/de active
- 2005-05-10 CN CN200580007686A patent/CN100577648C/zh not_active Expired - Fee Related
- 2005-05-10 AU AU2005251982A patent/AU2005251982B2/en not_active Ceased
- 2005-05-10 PL PL05770962T patent/PL1747201T3/pl unknown
- 2005-05-10 ES ES05770962T patent/ES2315898T3/es active Active
- 2005-05-10 BR BRPI0508563-2A patent/BRPI0508563A/pt not_active IP Right Cessation
- 2005-05-10 JP JP2007512277A patent/JP4909889B2/ja not_active Expired - Fee Related
- 2005-05-10 CA CA2557942A patent/CA2557942C/fr not_active Expired - Fee Related
- 2005-05-10 SI SI200530546T patent/SI1747201T1/sl unknown
- 2005-05-10 KR KR1020067018339A patent/KR101165483B1/ko not_active IP Right Cessation
- 2005-05-10 EP EP05770962A patent/EP1747201B8/fr active Active
- 2005-05-10 PT PT05770962T patent/PT1747201E/pt unknown
- 2005-05-10 DK DK05770962T patent/DK1747201T3/da active
- 2005-05-10 NZ NZ549330A patent/NZ549330A/en not_active IP Right Cessation
- 2005-05-10 RU RU2006132325/04A patent/RU2379293C2/ru not_active IP Right Cessation
- 2005-05-10 WO PCT/FR2005/001154 patent/WO2005121099A1/fr active Application Filing
- 2005-05-10 DE DE602005010418T patent/DE602005010418D1/de active Active
- 2005-05-10 RS RSP-2009/0012A patent/RS50724B/sr unknown
- 2005-05-10 TW TW094114981A patent/TWI349004B/zh not_active IP Right Cessation
- 2005-10-05 UA UAA200609699A patent/UA85866C2/uk unknown
-
2006
- 2006-08-15 TN TNP2006000258A patent/TNSN06258A1/fr unknown
- 2006-08-22 IL IL177632A patent/IL177632A/en not_active IP Right Cessation
- 2006-08-24 CR CR8570A patent/CR8570A/es unknown
- 2006-08-29 MA MA29294A patent/MA28372A1/fr unknown
- 2006-08-29 EC EC2006006810A patent/ECSP066810A/es unknown
- 2006-08-30 ZA ZA2006/07244A patent/ZA200607244B/en unknown
- 2006-09-11 NO NO20064073A patent/NO20064073L/no not_active Application Discontinuation
- 2006-10-13 US US11/549,293 patent/US7501449B2/en not_active Expired - Fee Related
-
2007
- 2007-08-28 HK HK07109361.5A patent/HK1104288A1/xx not_active IP Right Cessation
-
2009
- 2009-01-12 HR HR20090012T patent/HRP20090012T3/xx unknown
- 2009-01-14 CY CY20091100042T patent/CY1108710T1/el unknown
- 2009-01-27 US US12/360,535 patent/US8114899B2/en not_active Expired - Fee Related
-
2012
- 2012-01-11 US US13/348,241 patent/US8258168B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2624795T3 (es) | Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| CY1123308T1 (el) | Αναστολεας ινωσης | |
| CO6280509A2 (es) | Derivados de carboxamidas azabiciclicas su preparacion y su aplicacion en terapeutica | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| DOP2010000227A (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica | |
| NO20076006L (no) | Acetylenderivater | |
| UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
| CO6150146A2 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas su preparacion y su aplicacion en terapeutica | |
| AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| UY31014A1 (es) | Derivados de ftalazinona | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| UY30842A1 (es) | Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica | |
| ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| NO20083520L (no) | Tricykliske N-heteroaryl-karboksamidderivater inneholdende en benzimidazolenhet, fremgangsmate for fremstilling av samme og deres terapeutiske anvendelser | |
| NI200800015A (es) | Derivados de n-(heteroaril)-1-heteroarilalquil - 1h - indol - 2 - carboxamidas, su preparación y su aplicación en terapéutica. | |
| CR7950A (es) | Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas | |
| EA201170098A1 (ru) | Замещенные производные алкилпиримидин-4-она | |
| AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
| CO6150150A2 (es) | Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica | |
| UY32801A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии |